STOCK TITAN

NovaBay Pharmaceuticals, Inc. - $NBY STOCK NEWS

Welcome to our dedicated page for NovaBay Pharmaceuticals news (Ticker: $NBY), a resource for investors and traders seeking the latest updates and insights on NovaBay Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NovaBay Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NovaBay Pharmaceuticals's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.61%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.97%
Tags
Rhea-AI Summary
NovaBay Pharmaceuticals announces the acquisition of DERMAdoctor for $15.0 million. The acquisition is expected to double topline revenue in 2022 and drive profitability through operational synergies and a diversified product portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
conferences
NovaBay Pharmaceuticals, Inc.

NYSE:NBY

NBY Rankings

NBY Stock Data

3.42M
29.93M
0.04%
3.95%
2.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
EMERYVILLE

About NBY

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across